NSU And Immunotec Start Clinical Trial In Autism
The 2-year study will investigate the effects of a cysteine-rich whey protein isolate in children diagnosed with autism. The primary function of this research is to establish whether taking a 90-day diet of cysteine-rich whey proteins (which comes in a powder form), will have a positive effect on autistic behaviors. Improvements in affected behaviors may result in an enhanced quality of life for both children and their families. During the clinical study, there will be an analysis of the children's exhibited behaviors.
Autism is a neurodevelopmental disorder currently affecting as many as 1 in110 children in the United States. The conventional treatment for autism is centered on special schooling and behavioral therapy, and other conventional medical treatments. Whey protein isolate, which is used in this study, is a derivative of dairy product manufacturing, and is commonly used as a dietary supplement or food additive ingredient.
The NSU-Immunotec study's principal investigator is Ana Maria Castejon, Ph.D., who is an associate professor at NSU's College of Pharmacy. She and her research team are very enthusiastic about the potential outcomes of this study. "Parents and caregivers are trying different approaches that have gained significant popularity, but have not been proven to be effective," Castejon said.
Gary S. Margules, Sc.D., Nova Southeastern University vice president of research and technology transfer, called the study an "outstanding example of the multidisciplinary approach to clinical research".
Castejon is joined by co-investigators at NSU's Mailman Segal Center for Human Development. These researchers have vast experience in children with developmental disorders, specifically in the area of autism behavior.
"We are delighted to have the opportunity to collaborate with Dr. Margules, Dr. Castejon and their research team. This joint collaborative clinical research initiative marks an important milestone for Immunotec in the field of autism," said John Molson, Vice- President Research & Development at Immunotec Inc.
Source: Nova Southeastern University
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Nova Southeastern University. "NSU And Immunotec Start Clinical Trial In Autism." Medical News Today. MediLexicon, Intl., 31 Mar. 2011. Web.
26 Apr. 2017. <http://www.medicalnewstoday.com/releases/220749.php>
Nova Southeastern University. (2011, March 31). "NSU And Immunotec Start Clinical Trial In Autism." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.